Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Big-Pharma Defection Continues

In a continuation of a developing trend, two big-pharma executives left their cozy corner offices for the fast and wild biotech world. This year we have already seen a number of big names defect for the biotech world, the reasons … Continue reading

Posted in Executive Appointments, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , | Leave a comment

Biotech Investors Follow Pattern in Funding and Hiring Executives

Written by: Karl Simpson To be blunt, biotechnology ventures require lots of capital, and although alternative funding sources are now more accessible, money has traditionally come from the venture capital firms. These venture firms exercise differing strategies in allocating risk … Continue reading

Posted in Board Director Appointments, Executive Appointments, M&A Finance and Funding, Workplace Diversity | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Pharming snares ex-Karolinska Development CFO

Pharming Group NV (EURONEXT: PHARM) proposed the election of Mr Robin Wright as the Company’s new Chief Financial Officer (CFO) and member of the Management Board at an Extraordinary General Meeting (“EGM”) of shareholders, to be held on Wednesday 28 … Continue reading

Posted in Board Director Appointments, Executive Appointments | Tagged , , , , , , | Leave a comment

Agilis Biotherapeutics Strengthens Board of Directors

Agilis Biotherapeutics a biotechnology company in Cambridge, Massachusetts  which is advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), appointed Arthur Tzianabos, Ph.D. to the Company’s Board of Directors. Dr. Tzianabos already serves on … Continue reading

Posted in Board Director Appointments | Tagged , , , , , , , , | Leave a comment

Annie Chen Appointed CMO at Nimbus Therapeutics

Nimbus Therapeutics, a biotechnology company focused on harnessing the power of computational chemistry to design breakthroughs for serious, underserved diseases, today announced the appointment of Annie C. Chen, M.D., M.P.H., as Chief Medical Officer. Dr. Chen brings more than a … Continue reading

Posted in Executive Appointments | Tagged , , , , , , , | Leave a comment

Audion Therapeutics has Investors Listening

Audion Therapeutics is a Netherlands based biotech developing therapeutics in the area of hearing loss, an area that has garnered serious interest from investors against the backdrop of an ageing population. This investor sentiment has meant that Audion Therapeutics was … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , | Leave a comment

Sanofi Genzyme Bioventures announce a brace of deals

Sanofi Genzyme Bioventures announced to financing deals today (Sept 8 – 2015), as it contributed to the financing of Proteostasis Therapeutics, a Series B mezzanine round of $37m to the company developing a cystic fibrosis drug for the orphan disease. … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , | Leave a comment

Selecta Biosciences recruits $38m Series E and CMO

Selecta Biosciences raises $38m in Series E funding and also appoints Earl (‘Skip’) Sands, MD, as Chief Medical Officer (CMO). The company is a clinical stage biotech developing a novel class of targeted antigen-specific immune therapies. Proceeds from the financing … Continue reading

Posted in Executive Appointments, M&A Finance and Funding | Tagged , , , , , , , , , , | Leave a comment

Flex Pharma adds Cubist executive to Board of Directors

Robert J. Perez, former Chief Executive Officer of Cubist Pharmaceuticals, Inc., has joined its Board of Directors at Flex Pharma, a biotech which is developing therapies for exercise associate muscle cramps, nocturnal leg cramps, an neuromuscular related spasms. Mr. Perez … Continue reading

Posted in Board Director Appointments | Tagged , , , , , , , | Leave a comment

Wellstat Therapeutics given FDA nod for XURIDEN in Rare Disease

Wellstat Therapeutics Corporation has announced in September that the US Food and Drug Administration granted marketing approval for XURIDEN™ (uridine triacetate), a pyrimidine analog for uridine replacement indicated for the treatment of hereditary orotic aciduria (HOA). With the approval of … Continue reading

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap